With an increasing number of clinical trials ongoing, and initial clinical results from first-generation agonists enabling the industry to better understand the mechanisms of the targets, scientists are calling for more mechanistic understanding of the target biology to design the optimal formats.
The 2nd Annual Agonist Immunotherapy Targets conference will showcase the expanding formats and design principles to approach these agonist targets and pathways; discuss strategies to enhance specificity and reduce toxicity; and present the latest updates and lessons learned from molecules in the clinic.
Coverage will include, but is not limited to:
- Mechanistic Understanding of the Targets
- How these signal complexes organize?
- How molecules interact?
- Distribution and delivery of the molecules
- How does the desired agonist MOA and target biology impact discovery strategy?
- How to determine the optimal format (ligand-fusion, Fc-modified, bispecific etc) of the final candidate?
- Formats and Approaches Toward Agonist Targets and Pathways
- 4-1BB, OX40, CD40, ICOS, Cytokines, IL2, TLR, TNR-SF, GITR, STING, LIGHT, TRAIL, Oncolytic Viruses
- Molecules in the Clinic – Monotherapy and Combination Therapies
- 4-1BB, OX40, CD40, ICOS, TLR, Oncolytic viruses etc - how much activity is happening/not happening?
- What’s happening in the tumor microenvironment?
- Enhancing specificity and reducing toxicity of the agonists in the tumor microenvironment
- Controlling specific activity of immune cells in tumor context
- Balancing activity and toxicity
- Mouse in vivo Data of Single vs Combination Studies
- Is the in vitro data translating to in vivo?
- How to evaluate agonists that lack mouse cross-reactivity?
* The program is subject to change without notice, due to unforeseen reason.